Shares of Amazon (AMZN) have gained 10.2% over the past four weeks to close the last trading session at $234.69, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $294.4 indicates a potential upside of 25.4%.The average comprises 55 short-term price targets ranging from a low of $230.00 to a high of $340.00, with a standard deviation of $21.18. While the lowest estimate indicates ...

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) has seen a 2.3% increase in share price over the past four weeks, closing at $7.04, with analysts suggesting a potential upside of 234.7% based on a mean price target of $23.56 [1] Price Targets - The average price target from nine analysts ranges from a low of $16.00 to a high of $34.00, with a standard deviation of $5.68, indicating a potential increase of 127.3% to 383% from the current price [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about DAWN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.6%, with one estimate moving higher and no negative revisions [12] Zacks Rank - DAWN currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which serves as a strong indicator of potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - MBX Biosciences, Inc. (MBX) shares have increased by 2.6% over the past four weeks, closing at $17.96, with a potential upside of 228.5% based on Wall Street analysts' mean price target of $59 [1] Price Targets - The average of eight short-term price targets ranges from a low of $30.00 to a high of $84.00, with a standard deviation of $17.91, indicating variability among analysts [2] - The lowest estimate suggests a 67% increase from the current price, while the highest estimate indicates a 367.7% upside [2] Analyst Consensus and Earnings Estimates - Analysts show strong agreement that MBX will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, one earnings estimate has increased, leading to a 3.8% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - MBX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Acadia Pharmaceuticals (ACAD) has shown a recent price increase of 7.8% over the past four weeks, with a mean price target of $29.35 indicating a potential upside of 27.7% from its current price of $22.99 [1] Price Targets and Analyst Consensus - The average price target consists of 20 estimates ranging from a low of $17.00 to a high of $39.00, with a standard deviation of $5.55, indicating variability among analysts [2] - The lowest estimate suggests a decline of 26.1%, while the highest indicates a potential upside of 69.6% [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about ACAD's earnings prospects, as indicated by a trend of upward revisions in EPS estimates, which historically correlates with stock price movements [11] - Over the last 30 days, two earnings estimates have increased, leading to a 0.5% rise in the Zacks Consensus Estimate for the current year [12] - ACAD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely predict actual stock price movements accurately [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Monopar Therapeutics Inc. (MNPR) has seen a 21.2% increase in share price over the past four weeks, closing at $77.15, with a potential upside of 42.5% based on Wall Street analysts' mean price target of $109.91 [1][4]. Price Targets - The average of 11 short-term price targets ranges from a low of $85.00 to a high of $142.00, with a standard deviation of $17, indicating variability among analysts [2]. - The lowest estimate suggests a 10.2% increase from the current price, while the highest estimate indicates an 84.1% upside [2]. Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about MNPR's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 5.9% over the past month, with five estimates increasing and no negative revisions [12]. Zacks Rank - MNPR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [13]. Caution on Price Targets - While price targets are a common metric for investors, they should be approached with skepticism as they can often mislead, and analysts may set overly optimistic targets due to business incentives [3][7][10].

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) shows significant upside potential with a mean price target of $24.56, indicating a 241.6% increase from its current price of $7.19 [1] Price Targets and Analyst Consensus - The average price target consists of nine estimates ranging from a low of $16.00 to a high of $34.00, with a standard deviation of $5.36, suggesting a high degree of variability among analysts [2] - The lowest estimate indicates a potential increase of 122.5%, while the most optimistic estimate suggests a 372.9% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about DAWN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.4%, with one estimate moving higher and no negative revisions [12] - DAWN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research indicates that they rarely predict actual stock price movements accurately [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Company Overview - TD SYNNEX Corporation is a significant player in the business process services sector, distributing a variety of products including PC systems, mobile phones, IT systems, and consumer electronics. The company also offers systems design, logistics, cloud services, and marketing services to resellers, system integrators, and retailers, positioning itself as a key player in the technology distribution industry [1] Price Target Trends - The consensus price target for TD SYNNEX has shown an upward trend over the past year, increasing from $148.22 a year ago to $155.6 in the last quarter, and further to $173 in the past month, indicating growing optimism among analysts regarding the company's stock performance [2][6] Financial Performance - In the second quarter, TD SYNNEX reported strong financial results, surpassing guidance with significant revenue growth, improved profit margins, and impressive cash generation. The company's business model, focusing on scale and efficient management of working capital, supports its high-quality economic framework [3][6] Upcoming Earnings Report - The upcoming third-quarter earnings report is expected to reflect higher earnings for TD SYNNEX, with the stock having already increased by 5.8% since the last earnings report 30 days ago. Despite a lower price target of $130 from analyst Matthew Sheerin, the overall sentiment remains positive, with a valuation analysis suggesting a fair value between $170 and $175 [4][5] Investment Case - The strong financial performance of TD SYNNEX, along with a trailing free cash flow yield of 6% and steady dividend growth, strengthens the investment case for the company [5]

Core Viewpoint - Amneal Pharmaceuticals (AMRX) has seen a 22.1% increase in share price over the past four weeks, closing at $9.56, with a potential upside of 25.5% based on Wall Street analysts' mean price target of $12 [1][4]. Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.82, indicating variability among analysts [2]. - The lowest price target of $11.00 suggests a 15.1% increase, while the highest target of $13.00 indicates a potential surge of 36% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Market Sentiment - Analysts are optimistic about AMRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11]. - Over the last 30 days, three earnings estimates have been revised upward, leading to a 7.8% increase in the Zacks Consensus Estimate [12]. - AMRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10]. - Price targets can often be inflated due to business incentives, leading to overly optimistic projections [8].

Core Viewpoint - Thryv Holdings, Inc. (THRY) has seen a 16% increase in share price over the past four weeks, closing at $13.8, with analysts suggesting a potential upside of 55.1% based on a mean price target of $21.4 [1] Price Targets and Analyst Consensus - The average price target for THRY is based on five short-term estimates, ranging from a low of $16.00 to a high of $26.00, with a standard deviation of $4.1, indicating variability among analysts [2] - The lowest estimate suggests a 15.9% increase from the current price, while the highest estimate indicates an 88.4% upside [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7][10] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding THRY's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] - Over the last 30 days, one earnings estimate has increased, leading to a 27% rise in the Zacks Consensus Estimate for the current year [12] - THRY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of THRY's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - Aligos Therapeutics, Inc. (ALGS) closed at $8.77, with a 1.5% gain over the past four weeks, and a mean price target of $95 suggests a potential upside of 983.2% [1] - The mean estimate includes three short-term price targets with a standard deviation of $69.46, indicating variability; the lowest estimate of $50.00 suggests a 470.1% increase, while the highest target of $175.00 indicates a potential surge of 1895.4% [2] - Analysts agree that ALGS is expected to report better earnings than previously estimated, which strengthens the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for ALGS has increased by 14.9% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - ALGS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for price movement [14]